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Gomesin inhibits melanoma growth 
by manipulating key signaling 
cascades that control cell death  
and proliferation
Maria P. Ikonomopoulou1,2,3, Manuel A. Fernandez-Rojo1,2,3, Sandy S. Pineda  4,5,6, 
Pablo Cabezas-Sainz7, Brit Winnen4, Rodrigo A. V. Morales3,8, Andreas Brust4, Laura Sánchez7, 
Paul F. Alewood4, Grant A. Ramm  1,2, John J. Miles1,2,9 & Glenn F. King4
Consistent with their diverse pharmacology, peptides derived from venomous animals have been 
developed as drugs to treat disorders as diverse as hypertension, diabetes and chronic pain. Melanoma 
has a poor prognosis due in part to its metastatic capacity, warranting further development of novel 
targeted therapies. This prompted us to examine the anti-melanoma activity of the spider peptides 
gomesin (AgGom) and a gomesin-like homolog (HiGom). AgGom and HiGom dose-dependently 
reduced the viability and proliferation of melanoma cells whereas it had no deleterious effects on non-
transformed neonatal foreskin fibroblasts. Concordantly, gomesin-treated melanoma cells showed a 
reduced G0/G1 cell population. AgGom and HiGom compromised proliferation of melanoma cells via 
activation of the p53/p21 cell cycle check-point axis and the Hippo signaling cascade, together with 
attenuation of the MAP kinase pathway. We show that both gomesin peptides exhibit antitumoral 
activity in melanoma AVATAR-zebrafish xenograft tumors and that HiGom also reduces tumour 
progression in a melanoma xenograft mouse model. Taken together, our data highlight the potential of 
gomesin for development as a novel melanoma-targeted therapy.
Arthropods are the most abundant and widely distributed group of animals on earth. Within this group, spiders 
are one of the most speciose taxa, with over 47,000 species described to date1. Over a period of more than 400 
million years2, spiders have evolved a myriad of venom peptides that are used for prey capture and/or defense 
against predators, as well as hemocyte-derived host-defense peptides that play a key role in innate immunity3.
According to the ArachnoServer database4, more than 40 antimicrobial peptides have been isolated from 
spider venoms. Despite their sequence diversity, all of these peptides are small (1.9–8.6 kDa) and highly cati-
onic (pI 9.7–11.8). Moreover, in striking contrast with venom-derived peptide neurotoxins, all but four of these 
antimicrobial peptides are devoid of disulfide bonds. They are typically amphipathic and broadly cytolytic. They 
appear to be structurally disordered in aqueous solution but adopt an α-helical conformation in the presence of 
phospholipid membranes5. From an evolutionary perspective, it is striking that the vast majority of these anti-
microbial peptides (39 in total) were isolated from the venoms of araneomorph (“modern”) spiders. The three 
exceptions are disulfide-rich neurotoxic peptides isolated from venom of the Chilean rose tarantula Grammostola 
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rosea, a mygalomorph (“primitive”) spider. However, the antimicrobial activity of these peptides is likely to be 
secondary to their neurotoxic function.
Gomesin (AgGom), an antimicrobial peptide isolated from hemocytes of the South American mygalomorph 
spider Acanthoscurria gomesiana6, provides a striking contrast to the majority of antimicrobial peptides described 
to date; although small (18 residues) and highly cationic (pI 12.6, net charge + 6), gomesin it is not significantly 
amphipathic and it forms a well-defined tertiary structure comprising a β-hairpin that is stapled at each end by 
a single disulfide bond7. Moreover, both its N- and C-termini are protected by posttranslational modification 
(N-terminal pyroglutamate and C-terminal amidation). AgGom shares sequence and structural homology with 
the antimicrobial tachyplesin and polyphemusin peptides found in the hemocytes of horsehoe crabs6,8. Thus, 
AgGom belongs to an ancient and widespread family of invertebrate host-defense molecules. Hemocytes secret-
ing AgGom have been shown to play a role in host defence against microbes3.
A myriad of activities have been reported for AgGom, including antibacterial, antifungal, and anthelminthic 
activities6,8–10. Although it possesses broad antimicrobial activity, AgGom is not as potent as the related tachyples-
ins and polyhemusins8. However, in contrast with most antimicrobial peptides, AgGom is not hemolytic and it is 
only weakly cytotoxic to HepG2 and HEK293 cells8. Perhaps more interesting from a therapeutic perspective is 
the report that AgGom is cytotoxic to a range of murine and human tumor cell lines, with topical gomesin shown 
to delay development of subcutaneous murine melanomas11. However, it remains to be determined how AgGom 
affects the molecular pathways driving cell proliferation and growth of melanomas.
Melanoma is an aggressive form of skin cancer with heterogeneous aetiology. It generates significant morbid-
ity in part due to its high rate for developing chemoresistance12. In the US according to Skin Cancer Foundation 
statistics, one in every five Americans will develop skin cancer in their lifetime. Australia and New Zealand 
have the highest rates of melanoma in the world with an estimated 71 cases per 100,000 people, which translates 
to ~13,000 new cases every year13. Approximately 40–60% of all cutaneous melanomas carry mutations in the 
BRAF gene that cause constitutive activation of downstream mitogen-activated protein kinase (MAPK) signal-
ling14. Approximately 90% of mutations in the BRAF gene result in the substitution of Glu for Val at codon 600 
(BRAFV600E)14. BRAF encodes a RAS-regulated kinase that mediates cell growth and malignant transformation, 
and thus it is a promising drug target for treatment of melanoma15.
In this study, we investigated the anticancer properties of AgGom and a gomesin homolog (HiGom) in the 
melanoma cell line MM96L that contains the BRAFV600E mutation. We shed light on the anticancer potency of 
these naturally occurring antimicrobial peptides and evaluate their functionality via a melanoma preclinical drug 
discovery platform. We show that gomesin peptides activate the Hippo signalling cascade and increase the cel-
lular levels of the p53 and p21 cell cycle check-point proteins, whereas the MAPK pathway remains inhibited. 
Interestingly, gomesin peptides also activate the mTORC1, mTORC2 and AKT signalling pathways. We hypoth-
esise that this activation occurs as a compensatory mechanism to prevent gomesin-induced apoptosis of MM96L 
cells. We determined that gomesin peptides reduce viability in a panel of BRAF-mutated melanoma cell lines and 
demonstrated that HiGom has more profound antiproliferative properties than AgGom in the tested melanoma 
lines. Both gomesin peptides abolished cell viability in two BRAF wild-type cell lines. Finally, we utilised two 
unrelated but complementary animal models namely the AVATAR-zebrafish and mouse xenograft models of 
melanoma, to study the antitumoral effect of gomesin peptides. Both peptides reduced tumor progression in the 
AVATAR-zebrafish xenograft model while in the mouse xenograft melanoma model we tested only HiGom (as a 
more powerful analogue) and showed that it limits tumour progression.
Results
Identification of venom-gland transcripts encoding gomesin. Sequencing and analysis of a ven-
om-gland transcriptome from the Australian funnel-web spider Hadronyche infensa resulted in identification 
of numerous transcripts encoding toxins, putative toxins and proteins, most of which are likely associated with 
prey capture and defense. Amongst these transcripts, a cluster with seven reads was found to encode an ortholog 
(herein, HiGom) with sequence homology to that of the antimicrobial peptide gomesin (AgGom) isolated from 
hemocytes of the unrelated mygalomorph spider Acanthoscurria gomesiana (Fig. 1a).
Figure 1. (a) Schematic of 84-residue precursor encoding the gomesin homolog HiGom. The signal 
peptide, mature gomesin, and propeptide are shown in magenta, black and green, respectively. Note that 
Z = pyroglutamate. (b) Sequence alignment showing amino acid identities (boxed in black) between HiGom 
and AgGom. Disulfide bond connectivities are shown above the alignment. (c) Schematic of the AgGom 
structure showing the disulfide-stabilized β-hairpin (PDB file 1KFP).
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The HiGom transcript encodes an 84-residue prepropeptide precursor comprised of a 23-residue signal pep-
tide that precedes a single copy of the mature 18-residue HiGom peptide followed by a large propeptide region 
(Fig. 1a). The mature HiGom peptide contains an N-terminal Gln residue that we presume is post-translationally 
modified to pyroGlu as in the case of AgGom6. In addition, the propeptide region of the HiGom precursor 
contains a “KR” amidation signal immediately downstream of the final Arg residue in the mature toxin, and 
thus we predict that HiGom is C-terminally amidated like AgGom. The four-cysteine residues that form the 
two-disulfide bonds in AgGom are conserved in HiGom and homology modelling confirms that HiGom adopts 
the same disulfide-stapled β-hairpin structure as AgGom (Fig. 1b,c). We were unable to detect HiGom in milked 
venom, consistent with the low abundance of HiGom transcripts. However, although we did not recover any 
hemocycte-specific transcripts in the venom-gland transcriptome, we cannot exclude the possibility that the 
HiGom transcripts we identified arose from a small number of contaminating hemocytes in the venom gland 
preparation.
Antimicrobial and hemolytic activity of AgGom and HiGom. AgGom and HiGom were chemically 
synthesized, oxidized to form the two disulfide bonds, and purified to >98% homogeneity using reverse-phase 
HPLC. To demonstrate functional homology between HiGom and AgGom, we tested the antimicrobial activity of 
both peptides against a variety of Gram-positive and Gram-negative bacteria (Table 1). Both AgGom and HiGom 
were active against Gram-positive and Gram-negative bacteria and in all cases HiGom was either equipotent with, 
or more active than, AgGom (Table 1). Both peptides were highly active against the soil firmicutes Bacillus subtilis 
and Bacillus megaterium. Neither peptide was active against Streptococcus pneuomoniae or methicillin-resistant 
strains of Staphylococcus aureus. In addition, both gomesin peptides showed minimal hemolytic activity even at 
doses as high as 460 μg/mL (Supplementary Fig. 1). In comparison, melittin, a well-studied cytolytic toxin from 
bee venom16 is hemolytic at much lower concentrations (2–9 μg/mL; see Supplementary Fig. 1).
Gomesin peptides compromise the viability of BRAF mutated-melanoma cells. AgGom binds to 
cells with negatively charged outer membranes, including human MM96L melanoma cells, and forms pores in the 
membranes that decrease cell viability and proliferation17. To investigate whether HiGom shares similar cytotoxic 
properties, AgGom and HiGom were tested in melanoma BRAF-mutated MM96L cells and a non-transformed 
human neonatal foreskin fibroblast (NFF) cell line.
Treatment of MM96L cells for 48 h with 100 µg/mL AgGom or HiGom markedly reduced cell viability to < 5% 
(Fig. 2a). Similarly, reduced viability was observed in a panel of melanoma BRAF-mutated cells (MM96L, A2058, 
HTT144, JA, SKMEL28 and A02) at 50 µg/mL, with a more profound effect observed for HiGom (Supplementary 
Fig. 2). Importantly, treatment of MM96L cells with 3–50 µg/mL of AgGom or HiGom reduced MM96L viability 
without affecting the viability of NFF cells (ANOVA; F9,11 = 44.71; P < 0.0001) (Fig. 2b,c). HiGom had a stronger 
cytotoxic effect on MM96L cells than AgGom (EC50: 5.17 vs. 13.59 µg/mL, respectively; compare Fig. 2b,c), caus-
ing a significant decrease in MM96L viability at concentrations as low as 6.3 µg/mL (ANOVA, Bonnferroni’s 
multiple comparison test, F3,8 = 10.5; P = 0.038; Fig. 2c). Interestingly, we found that AgGom and HiGom are 
also highly cytotoxic to two BRAF wild-type cells (C001 and C002), suggesting that these peptides might have 
anti-proliferative activities in a wide range of melanoma cell types (Supplementary Fig. 3a,b). Moreover, to further 
assess the potential deleterious effects of AgGom and HiGom on a healthy skin cell line, we tested them in human 
melanocytes. While both peptides were lethal at 50 µg/mL (Supplementary Fig. 3c), they showed no cytotoxic 
MIC (μM) MBC (μM)
AgGom HiGom AgGom HiGom
Gram-positive bacteria
Staphylococcus aureus ATCC 25923 >28 28 >28 28
Enterococcus faecalis ATCC 51299 VanB 28 14 28 14
Enterococcus faecalis Van A 7 3.5 7 7
Bacillus subtilis ATCC 6633 0.875 0.656 0.875 0.875
Bacillus megaterium ATCC 13632 ≤0.014 ≤0.014 ≤0.014 ≤0.014
Streptococcus pneumoniae ATCC 33400 >28 >28 >28 >28
Staphylococcus aureus ATCC 43300 MRSA >28 >28 >28 >28
Staphylococcus aureus ATCC 29213 MRSA >28 >28 >28 >28
Staphylococcus epidermidis GISA 14 7 14 7
Gram-negative bacteria
Escherichia coli ATCC 25922 14 14 14 14
Klebsiella pneumonia ATCC 700603 >28 28 >28 28
Klebsiella pneumoniae ATCC 13883 14 7 14 7
Pseudomonas aeruginosa ATCC 10145 >28 >28 >28 >28
Table 1. Antimicrobial activity of gomesin peptides from A. gomesiana (AgGom) and H. infensa (HiGom) 
against a range of Gram-positive and Gram-negative bacteria. MIC = minimal inhibitory concentration. 
MBC = minimal bactericidal concentration. Three independent experiments were performed, each in 
triplicates.
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effects at a concentration of 12.5 µg/mL (Supplementary Fig. 3d), a dose that effectively reduced MM96L mela-
noma cell viability (Fig. 2b,c).
Gomesin peptides stimulate production of reactive oxygen species (ROS) and reduces mito-
chondrial membrane potential, resulting in late cell apoptosis. FACS was used to examine cell 
cycle progression in MM96L cells after 24 h exposure to 50 µg/mL AgGom or HiGom (i.e., the highest concen-
tration that is non-toxic to NFF; Fig. 2b,c). In comparison to vehicle-treated cells, AgGom and HiGom-treated 
MM96L cells were in G0/G1 phase (t-test: DF = 6, P = 0.0112; P = 0.0404, respectively) and a greater number 
were arrested in S-phase (t-test: AgGom: p = 0.035; HiGom: p = 0.57, respectively) (Fig. 2d); thus, both gomesin 
peptides reduce cell proliferation at G0/G1-phase while AgGom caused cell cycle arrest at S-phase.
Treatment of MM96L cells with 50 µg/mL AgGom or HiGom increased the number of late apoptotic cells 
by 2.7-fold compared to untreated cells (ANOVA, F3,15 = 7.393, P = 0.0029;) (i.e., AgGom: 47.7 ± 2.3, HiGom: 
48.18 ± 9.1; Untreated: 17.4 ± 1.7; Fig. 3a). A similar result was seen using camptothecin, a well-known cyto-
toxic natural compound that induces apoptosis in cancer cells18 (Fig. 3a). The number of healthy cells decreased 
by 1.8- and 1.7-fold in AgGom- and HiGom-treated MM96L, respectively, compared to vehicle-treated cells 
(AgGom: 42.5 ± 1.4; HiGom: 38.85 ± 8.8; Untreated: 76.6 ± 2.4; ANOVA, F3,15 = 9.701, P = 0.0008) (Fig. 3a). 
However, no significant stimulation of early apoptosis or necrosis was observed in response to either gomesin 
peptide. Accordingly, analysis of pro-apoptotic markers at early stages of gomesin treatment (24 h, 50 µg/mL) 
did not reveal an increase the levels of cleaved PARP and caspase 3 or of Bax and Puma (Fig. 3b), implying that 
either apoptosis was not initiated at 24 h or that apoptosis is independent of the caspase 3 pathway. Interestingly, 
while the ROS output in vehicle-treated cells was minimal, MM96L cells exposed to AgGom or HiGom for 24 h 
generated a significant amount of ROS that may explain their apoptotic profile after 48 h (ANOVA, F3,10 = 8. 584, 
P = 0.0041) (Fig. 3c). Pre-incubation of MM96L cells with mitoTEMPO, a specific inhibitor of mitochondrial 
ROS production, prior to gomesin treatment prevented ROS production, consistent with HiGom stimulating 
ROS generation (t-test: t = 8.459, df = 2, p = 0.037) (Fig. 3d). As expected, a significant decrease in Rhod-123 
fluorescence confirmed that the elevated generation of ROS in response to gomesin peptides was accompanied by 
a significant loss of mitochondrial membrane potential integrity (Kolmogorov-Smirnov test, AgGom: P = 0.0079; 
HiGom: P = 0.008) (Fig. 3e).
Figure 2. Gomesin peptides dramatically reduce viability of MM96L and BRAF-wild type cells. (a) Viability of 
MM96L cells treated with 100 µg/mL of AgGom or HiGom for 48 h, compared to cells treated with 0.1% SDS and 
untreated cells (b,c). Dose-response data for treatment of MM96L and NFF cells for 48 h with (b) AgGom or (c) 
HiGom. (d) Effect of gomesin peptides on cell cycle progression. MM96L cells were treated with 50 μg/mL AgGom 
or HiGom for 24 h. Changes in cell cycle (SubG0, G0/G1, S and G2/M phases) were analysed using the FloJow 
10.06 program. Data are shown as mean ± SEM. Experiments were performed in triplicate and are the result of 
three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (MM96L vs NFF).
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Gomesin peptides inhibit the MAPK pathway but stimulate the Hippo pathway and p53/p21 
axis. We examined the molecular signaling cascades underlying the anti-proliferative and pro-apoptotic 
activities of AgGom- and HiGom-treated MM96L. We focused our investigations on the Hippo, AKT, mTOR 
and MAPK signalling pathways that have been described to mediate proliferation in melanoma cells19–21. The 
Hippo pathway regulates cell proliferation and controls organ size and growth by cytosolic sequestration and 
inhibition of the pro-proliferative activity of Yes-associated protein (YAP), via phosphorylation of YAP at Ser127 
(P-YAPSer127). Deregulation of the Hippo pathway and subsequent translocation of dephosphorylated YAP into 
the nucleus has been linked to the development of several types of cancer21. Examination of this pathway in 
cultured MM96L cells revealed elevated levels of P-YAPSer127 in the presence of AgGom and HiGom (Fig. 4a), an 
indication that gomesin peptides activate the Hippo pathway to retain YAP in the cytosol and thus prevent its 
pro-proliferation activities.
In addition, AgGom and HiGom almost abolished phosphorylation of the p42/44 protein, suggesting that 
these peptides inhibit the MAPK pathway (Fig. 4b), a well-known molecular pathway that drives cell proliferation 
in cancer cells22. Subsequent analysis of the check-points responsible for normal cell cycle progression revealed 
elevated levels of p53 and p21 but not p27 in AgGom- and HiGom-treated MM96L cells (Fig. 4c). Gomesin 
peptides did not affect CyclinD1, a G1-phase marker. However, cell cycle arrest correlated with mildly decreased 
levels of the proliferating cell nuclear antigen (PCNA) (Fig. 4d), a marker of the progression of cells into S-Phase.
Figure 3. AgGom and HiGom induce late apoptosis of MM96L cells. (a) Apoptosis of MM96L cells incubated 
AgGom or HiGom (50 μg/mL for 48 h) was assessed using an Annexin V-FITC assay. Both peptides significantly 
increased the number of late apoptotic cells (>50%) in comparison to untreated cells. Cells treated with 
camptothecin (25 µM, 24 h) were used as a positive control. (b) Representative western blots and protein 
quantification from three independent experiments showing the pro-apoptotic cell markers cleaved Caspase-3, 
Puma, Bax and Tubulin in MM96L cells incubated with AgGom or HiGom (50 μg/mL, 24 h). (c) Gomesin 
peptides (50 μg/mL, 24 h) increased ROS production in MM96L cells as measured by flow cytometry. (d) 
MM96L cells were pre-treated for 2 h with mitoTEMPO prior to addition of 50 μg/mL AgGom or HiGom. Cells 
had reduced ROS production compared to cells treated with AgGom or HiGom alone. (e) The mitochondrial 
membrane potential of MM96L cells was reduced after treatment with AgGom or HiGom (50 μg/mL, 24 h). 
Data are shown as mean ± SEM and are the result of a minimum of three independent experiments performed 
in triplicate or duplicate (cell cycle experiments). Statistical analyses are relative to untreated cells and are 
represented as: *P < 0.05, **P < 0.01, ***P < 0.001.
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Activation of pro-survival AKT and mTOR signaling in response to gomesin peptides. Paradoxically, 
we found that AgGom- and HiGom-treated cells exhibited over-phosphorylation of AKT at Ser473 (AKTSer473) 
(Fig. 4e). While AKT phosphorylation and activation contribute to cell proliferation, they also constitute an 
anti-apoptotic molecular mechanism23. Indeed, it has been postulated that the primary function of the major AKT 
isoform, AKT1, is to promote cell survival. Since we demonstrated that AgGom and HiGom arrest melanoma cell 
proliferation, we suggest that activation of AKT signaling might be a compensatory cell survival mechanism to pre-
vent apoptosis. Thus, we examined the molecular circuits underlying activation of AKT signaling for cell survival that 
comprises mTORC2- and mTORC1-target p70 S6Kinase. mTORC2 fully activates AKT by mediating phosphoryla-
tion at AKTSer473 24. In AgGom- and HiGom-treated MM96L cells we observed increased phosphorylation of Rictor at 
Thr1135 (Fig. 4f), implying mTORC2 activation25,26. The phosphorylation of Rictor at Thr1135 is mediated by phos-
phorylated p70S6 kinase at Thr389 (P-p70S6KThr389) (Fig. 4f), which depends on activity of the mTORC1 complex25–27. 
Accordingly, we observed an increase of P-p70S6KThr389 as well as an elevated phosphorylation of the mTORC1-target 
4E-BP1 at Thr37/46 (P-4E-BP1Thr37/46) (Fig. 4g).
HiGom delays progressive growth of xenograft melanoma tumours. In order to evaluate the 
potential of gomesin peptides for development as therapeutic leads against melanoma we examined the ability 
of HiGom to limit progression of MM96L-melanoma tumour xenografts in immunodeficient nude mice. We 
chose HiGom over AgGom at 10 μg/kg for these studies based on its higher potency in melanoma cells and less 
deleterious effects on NFF and melanocytes cells in vitro (see Fig. 2b,c & Supplementary Fig. 2). Tumour progres-
sion was evaluated by assessing the fold-change in tumour volume every two days in comparison to the volume 
prior to initiation of HiGom treatment. We observed a significant delay in tumour growth in HiGom-treated 
versus PBS-treated mice (n = 10 tumours per group; permutation test, *p < 0.05) (Fig. 5a). In contrast to cul-
tured MM96L cells, we did not observe activation of the Hippo pathway or of the cell cycle markers PCNA, p53, 
p27 and p21 in the xenografted MM96L tumors of HiGom-treated mice compared to the vehicle-treated group 
(Fig. 5b).
We also exmained the anti-tumoral effects of AgGom and Higom in the AVATAR MM96L-xenograft tumor 
zebrafish model. Xenografted zebrafish embryos were intravenously injected with MM96L dil labeled cells to 
assess the efficacy of AgGom and HiGom on the proliferation and metastatic capacity of melanoma cells. At 
one-day post injection (dpi) the embryos were imaged and treated with 0.1 µg/mL of AgGom or HiGom, the 
Figure 4. Gomesin peptides activate the Hippo pathway, inhibit MAPK cascades, and stimulate the p53/p21  
cell cycle checkpoint axis. Representative western blots from three independent experiments showing: 
(a) Immunodetection of phospho-YAPSer127 in comparison to total YAP protein as a marker of the Hippo 
pathway; (b) Phospho-p42/44 (also called Phospho ERK) as a marker of the level of activation of the MAPK 
pathway; (c) PCNA, cyclin D1, p53, p21 and p27 as markers of the checkpoints that regulate progression of the 
proliferative cell cycle. Actin was used as a protein-loading marker; (d) Phospho-AKTSer473 in comparison to 
total AKT protein; (e) Phospho-RictorThr1135 in comparison to total Rictor protein as a marker of the activation 
of the mTORC2 complex/cascade which is responsible for phosphorylation of AKT at Ser473; (f) Phospho-
p70S6KThr389 in comparison to total p70S6K protein and Phospho-4E-BP1Thr37/46 in comparison to total 4E-BP1 
protein as markers of activation of the mTORC1 complex/cascade which is responsible for the phosphorylation 
of Rictor at Thr1135. MM96L cells were treated with 50 μg/ml AgGom (AgG) or HiGom (HiG) for 24 h. Right 
panel shows quantification of the western blots.
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maximum safe dose for the embryos (Supplementary Table 1). At 3 dpi the embryos were photographed again 
to allow comparison with images taken at 1 dpi in terms of total fluorescence (number of pixels in the image and 
the intensity of the fluorescence) and to measure the proliferation of the MM96L cells after being treated with 
AgGom or HiGom. Both AgGom and HiGom yielded a significant reduction (35% and 30%, respectively) in the 
proliferation of MM96L cells (*p < 0.05) compared to control cells, which translated into a significantly reduced 
tumor growth and invasive capacity of MM96L cells (Fig. 5c,d).
Discussion
Gomesin kills melanoma cells by induction of late apoptosis. Our investigations revealed that both 
AgGom and HiGom reduce the viability of melanoma cells at doses that are innocuous to non-transformed fibro-
blasts. HiGom exhibited greater anti-proliferative activity against a range of BRAF-mutated melanoma cell lines 
in vitro as well as lower cytotoxicity to NFF cells, making it a better candidate for development of an anti-mela-
noma drug. The different effect of AgGom and HiGom could be explained due to amplification of microphthal-
mia-associated transcription factor (MITF) expression in the different melanoma lines, which has been linked 
to MAPK inhibition28. Melanoma-bearing mice treated for eight days with HiGom showed significantly slower 
tumour progression in comparison to vehicle-treated controls. Consistent with this observation, it was previously 
shown that AgGom incorporated into a topical cream applied for approximately four weeks to C57BL/6 mice 
bearing B16F10-Nex2 subcutaneous tumours caused a significant delay in tumor progression11. However, the cur-
rent study is the first to show that gomesin peptides inhibit growth of human melanoma tumors in vivo. In addi-
tion, independent and unbiased validation of our mouse results in an AVATAR MM96L xenograft tumor model 
in zebrafish29 highlights the therapeutic potential of gomesin against human melanoma BRAF-mutated cells.
Figure 5. HiGom inhibits progression of xenografted human melanomas. (a) Nude mice bearing MM96L 
tumors were injected i.p. with 10 mg/kg HiGom or PBS (vehicle control group) at two-day intervals for a total of 
eight days, with tumour volume measured every two days and at the conclusion of treatment by digital callipers. 
Tumour progression was evaluated by assessing the fold-change in tumor volume every two days in comparison 
to the tumor volume observed prior to initiation of HiGom treatment. (b) Analysis of the signaling cascade in 
HiGom-treated in comparison to vehicle (PBS) treated- MM96L xenograft tumors. Ten mouse tumours per 
group were assessed. (c) Representative images of MM96L cells labeled with dil after 1-day post injection (1 dpi) 
and 3 dpi in zebrafish embryos treated with AgGom or HiGom at 0.1 μg/mL in comparison to the control (salt 
dechlorinated tap water exposed) embryos. The images are shown as contrast (grey scale) and fluorescent (black 
background) phase. (d) The proliferation ratio of MM96L cells treated with AgGom or HiGom at 0.1 μg/mL 
and the control (untreated) cells in AVATAR zebrafish models. All cells were labeled with dil staining. Data for 
mouse and zebrafish experiments are shown as mean ± SEM. *P < 0.05.
www.nature.com/scientificreports/
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AgGom and HiGom induce late apoptosis of melanoma cells. Apoptosis can be triggered as a cellular response 
to oxidative stress, caused by an imbalance between excessive ROS production and the response of the antioxida-
tive defence mechanisms of cells30. While ROS output in vehicle-treated MM96L cells was minimal, a 24 h expo-
sure to either AgGom or HiGom significantly elevated ROS production, which may in part explain the apoptotic 
effects of these peptides. Previous reports have linked increased intracellular ROS production and mitochondrial 
malfunction leading to apoptosis in AgGom-treated CHO cells31, as well as loss of mitochondrial membrane 
potential and cellular apoptosis related to the mitochondrial pathway in melanoma cells32. We found that that 
gomesin-treated MM96L cells had reduced mitochondrial membrane potential, and that gomesin-induced ROS 
production could be reversed by pre-treatment with mitoTEMPO. Taken together, our data suggest that gomesin 
peptides might impair mitochondrial function resulting in cell apoptosis.
Mechanism of gomesin-induced death of melanoma cells. This is the first study to provide mech-
anistic details of how the arachnid-derived gomesin peptides, initially characterized as having antimicrobial, 
antifungal and anthelmintic activities, exhibit antiproliferative properties against human melanoma. We stud-
ied signaling cascades known to drive proliferation of melanoma cells, including the Hippo, AKT and MAPK 
pathways19–21.
The Hippo pathway mediates organ size and tissue growth by exerting strict control on the cellular prolifera-
tion rate. Consequently, Hippo pathway deregulation has been directly linked to the development of several types 
of cancer33. The transcription factor YAP is widely recognized as the central mediator of the pro-tumorigenic 
effects of Hippo pathway inactivation via its promotion of cell proliferation and inhibition of apoptosis33. To 
prevent the proliferative activity of YAP, the Hippo pathway via activation of the LATS1/2 kinases promotes 
phosphorylation of YAP at Ser127. This post-translational modification drives translocation of YAP from the 
nucleus to the cytoplasm, where it is sequestered through association with 14-3-3 proteins33. We showed that 
both AgGom and HiGom increase phosphorylation of YAP, thereby inhibiting the MAPK pathway22, a molecular 
pillar that sustains growth of human BRAF melanoma. We postulate that in order to inhibit proliferation and cell 
viability, and promote apoptosis in human BRAF MM96L cells, gomesin peptides coordinate activation of the 
Hippo pathway and inhibition of the MAPK signaling cascade.
AgGom and HiGom also enhance phosphorylation of AKT at Ser473 after 24 h, reflecting activation of the 
AKT pathway. The AKT signaling cascade is a pro-proliferative, anti-apoptotic pathway23. While activation of 
this pathway seems inconsistent with the pro-apoptotic profile of gomesin-treated MM96L cells observed at 48 h, 
we hypothesize that increased phosphorylation of AKT at Ser473 in response to 24 h of gomesin treatment might 
constitute a cell survival mechanism designed to delay apoptosis.
Cell survival and inhibition of pro-apoptotic signals is driven by P-p70S6KThr389 (refs34,35) and mTORC236. 
Our initial hypothesis postulated that the pro-survival activity of AKT might be the consequence of direct reg-
ulation of the mTORC1 target p70S6 kinase over the mTORC2 complex, which mediates phosphorylation at 
Ser473 and total activation of AKT. This hypothesis is supported by the fact that mTORC2 fully activates AKT by 
facilitating phosphorylation at AKTSer473 (refs25,26,37). Accordingly, we showed that MM96L cells treated for 24 h 
with AgGom or HiGom increased the levels of phosphorylated p70S kinase, which consequently phosphoryl-
ates Rictor at Thr1135 (ref.38). However, the significance of phosphorylation of Rictor at Thr1135 is a subject of 
current controversy. Independent studies have postulated three different theories regarding phosphorylation of 
Rictor at Thr1135: an inhibiting38, activating25 or an indifferent38 post-translational event for the activity of AKT. 
Hence, it is difficult to assess the functional role of mTORC2 in MM96L cells in response to gomesin treatment. 
Moreover, it is possible that p70S6KThr389 coordinates with AKT but in an AKT-independent manner34,35 to medi-
ate pro-survival signalling in gomesin-treated cells. In addition, it has been shown that Hippo pathway activation 
and cytoplasmic retention of YAP is an AKT-dependent mechanism33. Therefore, it is also feasible that active 
AKT contributes to Hippo pathway function in order to mediate the anti-proliferative effects of gomesin. Clearly, 
further investigations are warranted into the role played by AKT in gomesin-induced inhibition of melanoma cell 
proliferation.
Previous investigations have suggested that the cytotoxicity of AgGom and its enhancement of ROS produc-
tion in human neuroblastoma and rat pheochromocytoma cells is mediated via activation of the PI3K (which 
phosphorylates and contributes to the activation of AKT), MAPK and PKC signaling pathways39. These conclu-
sions were based on data showing that inhibitors of MAPK, PKC and PI3K ameliorated AgGom-induced ROS 
production and release of lactate dehydrogenase. However, in contrast to our in vitro assays which employed 
MM96L cells cultured in medium containing fetal bovine serum (10%), serum was absent from the culture 
medium in the study by Soletti and colleagues39. Since the culture of cells in serum-free media arrests cell pro-
liferation, some of the results observed by Soletti and colleagues could simply be off-target effects due to the 
lack of serum growth factors. Moreover, the lack of biochemical validation of these MAPK, PKC and PI3K 
inhibitors (i.e., examination of p42/44 and AKT phosphorylation as a readout of MAPK and PKC signaling) in 
AgGom-treated cells complicates interpretation of previous results. Nevertheless, it remains possible that AgGom 
engages different cell machinery in different tumors such as neuroblastoma and melanoma, which could explain 
the discrepancy between the two studies39.
Biochemical analysis of the signaling cascades controlling proliferation of MM96L indicate that AgGom and 
HiGom both arrest MM96L cells at S-phase and reduce the number of cells in G0/G1 phase. This is an intriguing 
and unusual phenotype since most cells are unable to enter S phase in response to cytotoxic agents. Interestingly, 
the cell-cycle phenotype of gomesin-treated MM96L cells mimics that induced by direct inhibitors of DNA rep-
lication such as hydroxyurea, fluorouracil and aphidicolin. In support of this analogy, analysis of the cell cycle 
checkpoints (i.e., p53, p21 and p27)40 and markers (cyclin D1 and PCNA)22,40 driving cell proliferation of MM96L 
cells, revealed that both gomesin peptides provoke cell cycle arrest through activation of the p53/p21 axis but not 
p27, which manifests as diminished expression of the S-phase marker PCNA41. p53 inhibits DNA replication42, 
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while p21 mediates cell cycle arrest in G2 (G2 exit) and leads to senescence43, which might contribute to the late 
apoptosis observed in gomesin-treated cells. Intriguingly, cyclin D1 remained at constant levels. This could either 
be because cells could progress from G0 to G1 but not to S-phase, or because cyclin D1 does not play a role in cell 
cycle progression in MM96L cells, as seen in resistant metastatic melanoma lines41.
Summary. This study is the first to demonstrate the potential of AgGom and HiGom in treating human 
melanoma containing BRAF mutations. We showed that gomesin peptides induce cell cycle arrest, reduce cell 
viability and stimulate apoptosis of MM96L cells. Mechanistically, our data revealed that gomesin exerts its 
anti-proliferative effect via three different molecular pathways: activation of the Hippo pathway, inhibition of 
MAPK cascades, and stimulation of the p53/p21 cell cycle checkpoint axis. In addition, activation of AKT might 
play a dual role by contributing to the Hippo pathway control of cell proliferation but as a survival signal that 
delays entry into apoptosis. Finally, our demonstration that gomesin inhibits the growth of human melanoma in 
two independent and unbiased in vivo melanoma xenograft tumor models suggests that it may have therapeutic 
utility.
Methods
Reagents. Fmoc–protected L-amino acids Arg(Tos), Asn(Trt), Cys(Trt), Cys(Acm), Gly, Leu, Lys(Boc), Thr, 
Tyr(tBu) and Val were purchased from Novabiochem (Sydney, Australia). Unprotected L-pyroglutamic acid, tri-
isopropylsilane (TIPS), diethyl ether, iodine, ascorbic acid and ammonium bicarbonate were purchased from 
Sigma-Aldrich (Sydney, Australia). Fmoc Rink-amide resin was obtained from the Peptide Institute (Osaka, 
Japan). O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluorophosphate (HBTU) was from Iris Biotech 
(Marktredwitz Germany), while N,N-dimethylformamide (DMF), trifluoroacetic acid (TFA), piperidine, and 
N,N-diisopropylethylamine (DIEA) were from Auspep (Melbrourne, Australia). HPLC-grade acetonitrile was 
obtained from Merck (Merck, Pty, Australia), bacterial culture media from Bacto Laboratories (Australia), and 
enzymes (vancomycin and colistin) from Invitrogen and Life Technologies (Australia).
All media for cell culture was purchased from Invitrogen/Gibco. For melanocytes we used complete media 
acquired from ThermoFisher. MitoTEMPO was from Cayman Chemicals (#16621). The majority of antibodies 
were obtained from Cell Signaling Technology including Rabbit anti-Phospho AKTSer473 (#4060), Total AKT 
(#4691), Phospho-YAPSer127 (#13008), Total YAP (#8418), p21 (#2947), p27 (#3696), and p53 (#2527). Puma was 
purchased from ProSci (#3043), Bax was obtained from Merck (#ABC11), Cyclin D1 (#2978), PCNA (#13110), 
Phospho-p42/44 (#4370), Total ERK (#4067), Phospho-RictorThr1135 (#3806), Total Rictor (#2114), Phospho-p70 
S6KThr389 (#9234), Total p70 S6K (#2708), Phospho-4E-BP1Thr37/46 (#2855), Total 4E-BP1 (# 9644), Caspase 
cleaved 3 (#9929), PARP cleaved (#9929), and actin (#4970) were from Cell Signaling Technology. Anti-rabbit 
HRP was from Sigma (#A0545).
Venom-gland transcriptome. Three days after milking to deplete their venom glands and stimulate toxin 
transcription, three spiders were anesthetized and their venom glands dissected out and immediately placed in 
TRIzol® reagent (Life Technologies). Total RNA was extracted and RNA quantity and integrity determined from 
the OD260/OD280 ratio and analysis on a Bioanalyzer 2100 Nano Chip (Agilent Technologies). mRNA enrichment 
from total RNA was performed using an Oligotex direct mRNA mini kit (Qiagen) following the manufactur-
er’s specifications. After elution, mRNA was precipitated with RNAse/DNAse-free ammonium acetate, glycogen 
and 95% ethanol. The resulting pellet was washed with 75% diethyl pyrocarbonate (DEPC)-treated ethanol and 
re-suspended in 25 μl of RNAse/DNAse-free water. Approximately 100 ng of mRNA was used to construct the 
cDNA library using the standard cDNA rapid library preparation and emPCR method recommended by Roche. 
After construction, libraries were sequenced by the Brisbane node of the Australian Genome Research Facility 
using a Roche GS FLX sequencer.
The Raw Standard Flowgram File (.SFF) was processed using Cangs software, and low quality sequences dis-
carded using a Phred score cut-off of 2544. De novo assembly was done using MIRA software v3.245 using the fol-
lowing parameters: -GE:not = 4–project = Hinfensa–job = denovo,est,accurate,454 454_SETTINGS -CL:qc = no - 
AS:mrpc = 1 -AL:mrs = 99,egp = 1. The assembled data set was visualized using TABLET or Geneious soft-
ware46,47. An “in-house” algorithm was used to predict open reading frames encoding disulfide-rich toxins. Signal 
sequences were determined using the SignalP algorithm48. Putative propeptide cleavage sites were predicted using 
a sequence logo analysis of all known spider precursors. Homology of transcripts was determined via BLAST.
Chemical synthesis of gomesin peptides. Gomesin peptides from A. gomesiana (AgGom) and 
H. infensa (HiGom) were synthesized manually at 0.2 mmol/g scale on a Rink amide linker loaded polystyrene 
resin using standard Fmoc solid-phase peptide synthesis (SPPS) protocols49. Selective disulfide formation was 
used to ensure that the native disulfide isomer of gomesin was obtained (i.e., CysI–CysIV, CysII–CysIII)7. To 
achieve selective disulfide pairing, Cys(Acm) was introduced in positions 6 and 11 whereas the cysteine resi-
dues in positions 2 and 15 were introduced as Cys(Trt). Briefly, at each cycle, the swollen resin was deprotected 
in 40% piperidine/DMF and coupled to the HBTU/DIAE-activated Fmoc amino acid for 20 min. At the end 
of the synthesis, the peptide chain was deprotected and cleaved from the protected peptide-resin using a solu-
tion of TFA:TIPS:water (90:5:5) for 3 h, then evaporated by a stream of N2. The crude peptide mixture was pre-
cipitated in ice cold diethyl ether and filtered. The crude peptide product was dissolved in a solution of 50% 
acetonitrile (ACN) acidified with 0.1% TFA, lyophilized, and purified using reversed-phase HPLC (RP-HPLC) 
(Supplementary Fig. 3a).
Folding via selective oxidation of each cysteine pair was achieved as shown in Supplementary Fig. 3a–c 49,50. 
The first disulfide bridge between Cys2 and Cys15 was formed by incubating the purified linear peptide in 
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100 mM ammonium bicarbonate (pH 8) at a final concentration of 0.1 mg/mL for 24 h. The partially folded pep-
tide was lyophilized and resuspended in 50:50 acetonitrile:water solution acidified with 0.01% TFA. The Cys6–
Cys11 disulfide bridge was then formed by dropwise addition of the peptide solution to an equal volume of 10 mM 
iodine dissolved in ACN/water/TFA (49:49:2). The reaction mixture was agitated for 20 min then quenched with 
ascorbic acid. The crude peptide was immediately purified using RP-HPLC. The formation of each disulfide 
bridge was monitored and confirmed using ES-LC-MS (ABI 150EX, AB-Sciex (See Supplementary Fig. 3b,c). 
Homogeneous peptide fractions were lyophilized and high-resolution mass data was obtained by LC-TOF-MS 
analysis (QSTAR Elite; AB-Sciex). AgGom had a monoisotopic mass of 2269.0734 (predicted = 2269.0717), 
while HiGom had a monoisotopic molecular mass of 2284.6972 (predicted = 2284.6950). Peptides were stored at 
−20 °C until further use.
Antimicrobial assays. The antibacterial activity of AgGom and HiGom was measured using a microtiter 
broth dilution method51. Briefly, Gram-positive and Gram-negative bacteria were cultured in Muller Hinton 
II broth at 37 °C. Overnight bacterial cultures were diluted 40-fold into fresh broth and incubated at 37 °C for 
2–3 h. The resultant mid-log phase cultures (OD600 ~0.6) were diluted to a final concentration of 5 × 105 colony 
forming units (CFU)/mL and added to assay wells containing 2-fold serial dilutions of synthetic gomesin. Plates 
were incubated at 37 °C for 24 h, and the minimum inhibitory concentration (MIC) was taken as the lowest 
concentration of gomesin that yielded no visible bacterial growth. Vancomycin and colistin at a concentration of 
1.28 mg/mL were used as positive controls. To determine the minimal bactericidal concentration (MBC), 30 µL 
of resazurin (0.01%) was added to each well after the MIC values were determined; then plates were further incu-
bated at 37 °C for 24 h. Wells with blue or pink colouration indicated dead or live bacteria, respectively. The MBC 
value was determined as the lowest gomesin concentration that yielded blue colouration. Assays were performed 
in triplicate.
Hemolytic assay. Hemolysis was monitored by adding synthetic gomesin (6.25–187 μM) to human erythro-
cytes (0.25% in phosphate buffered saline). 1% Triton-X100 was used as a positive control (100% lysis). Samples 
were incubated at 37 °C for 1 h, centrifuged at 400 g for 5 min, then the absorbance of the supernatant (100 μl) 
measured at 415 nm using a microtiter plate reader (BIOTEK PowerWave XS). Melittin (0–3.33 μM), a highly 
hemolytic bee-venom peptide, was used for comparison. Experiments were performed in triplicate.
Cell culture. The human melanoma cell lines MM96L, A2058, HTT144, JA, SKMEL28, A02, C001, C002 as 
well as the nontransformed NFF cell line and melanocytes were maintained in a humidified incubator at 37°C 
and 5% CO2. All melanoma cells were cultured in RPMI-1640 media supplemented with 10% FCS,and 2 mM 
GlutamaxTM. NFF cells were grown in RPMI-1640 containing 10% FCS and melanocytes were maintained in 
medium 254CF supplemented with Human Melanocyte Growth Supplement (HMGS). Penicillin/streptomycin 
(PS) (100 U/ml each) were added to all media. Cells were passaged at approximately 90% confluency. Functional 
studies were performed with passages up to 25. All cell lines were genotyped to ensure purity and absence of 
mycoplasma contamination.
Cell viability assay. Cell viability was measured via a commercial colorimetric assay based on the reduc-
tion of the yellow tetrazolium dye MTT (Sigma-Aldrich) to purple formazan by NAD(P)H-dependent 
oxido-reductases in living cells. Thus, MTT reduction is a reflection of the number of viable and proliferative 
cells. We assessed cytotoxicity by comparing melanoma (MM96L, A2058, HTT144, JA, SKMEL28, A02, C001, 
C002), melanocytes and NFF cells. Briefly, 2,500 or 5000 melanoma and 8,000 or 4,000 (NFF & melanocytes) 
cells/well were seeded in a 96-flat microtiter well plate for 24 h to allow cell adhesion. Gomesin peptides were then 
added and MTT reduction measured after 48 h from the absorbance at 540 nm measured on a microplate reader 
(BIOTEK PowerWave XS). 0.1% SDS was used as a positive control (100% toxicity). The concentration of gomesin 
peptide causing 50% inhibition (IC50) was determined was determined using GraphPad Software, Inc (USA).
Flow cytometry. MM96L cells were treated for 24 h with 50 µg/mL AgGom or HiGom, the maximum safe 
dose that killed MM96L cells but had minimal effect on NFF. Cells were then trypsinised, washed with PBS, and 
fixed with 70% ethanol for ~1 h at 4 °C. Ethanol was removed by centrifugation (453 g for 5 min), then cells were 
washed with PBS. Cells were then treated with 5 µl of 10 µg/ml ribonuclease A to remove contaminating RNA and 
were further incubated for 1 h at 37 °C to allow release of low-molecular weight DNA. Cell pellets were stained 
with 10 µl of propidium iodide (PI) (1 mg/ml stock) and analysed at a maximum emission of 605 nm using a BD 
LSR Fortessa 5 analyser (BD Biosciences). A minimum of 10,000 events were recorded. All data were analysed 
using FlowJo v10.06.
Apoptosis assay. The level of apoptosis in MM96L cells treated with AgGom or HiGom, was measured by 
FACS using an Annexin V-FITC apoptosis detection kit (BD Biosciences). Briefly, cells were seeded at a density 
of ~100,000 in a round-bottom 96-well plate and treated with 50 µg/mL AgGom or HiGom for 48 h. Cells were 
then harvested with accutase, and washed twice with PBS and once with wash buffer provided by the manufac-
turer. Cells were stained simultaneously with FITC-labeled annexin V and PI. Stained cells were kept in the dark 
at room temperature and analysed using a BD FACS Canto™ II high-throughput system (BD Biosciences) within 
30 min of staining.
ROS assay. An Amplex® Red Hydrogen Peroxidase assay kit (Invitrogen) was used to determine whether 
AgGom or HiGom caused intracellular toxicity in MM96L cells by generation of ROS, a known marker of intra-
cellular oxidative stress in response to environmental noxious conditions. Carboxy-H2DCFDA (Invitrogen), a 
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fluorescence probe that detects intracellular hydrogen peroxide, was added 30 min prior to harvesting cells to 
measure ROS production in MM96L cells. Fluorescent cells were first washed twice with PBS before being anal-
ysis with a BD FACSCalibur™ flow cytometer (BD Biosciences) using excitation and emission wavelengths of 
492 nm and 517 nm, respectively. Approximately 10,000 events were recorded per sample and the read-out was 
analysed using FlowJo v10.06. In a separate series of experiments, MM96L cells were pre-treated with 10 µM 
mitoTEMPO, a mitochondrially-targeted superoxide scavenger, for 2 h prior to gomesin addition.
Mitochondrial membrane potential. Rhodamine 123 (Rhod-123) is a cationic dye that is sequestered 
by mitochondria and thus can used to assay mitochondrial membrane potential (MMP). Loss of MMP results in 
loss of Rhod-123 fluorescence. MM96L cells (~1 × 106) were resuspended in 0.1 mL of culture medium, stained 
with 10 µg/m L Rhod-123 for 30 min, and then washed twice with PBS. The intracellular concentration of Rhod-
123 was then determined immediately via flow cytometry using an excitation wavelength of 488 nm. Data were 
analysed using FlowJo v10.06.
Western blots. MM96L cells were lysed in cold RIPA buffer containing protease (Merck Pty Ltd, Kilsyth, 
Australia) and phosphatase (Roche Diagnostics, Castle Hill, Australia) inhibitors and stored at −20 °C. Protein 
concentrations were determined using a Pierce BCA Protein assay kit (Thermo Fisher Scientific). Samples were 
subjected to SDS-PAGE and blotted according to standard procedures. In brief, 10 μg of protein was loaded per 
lane. Antibodies used for western blots are described in the Reagents section. Protein signals were visualized 
using enhanced chemiluminescence (Pierce™ ECL Western Blotting Substrate).
Animal studies. All mouse work methods were carried out in accordance with the QIMR Berghofer Medical 
Research Institute relevant ethical guidelines and regulations. In addition, all experimental protocols were 
approved by the QIMR Berghofer Medical Research Institute Ethics and Animal Committees (Project P2109 & 
Ethics Permit A15605).
To determine the maximum safe dose of HiGom, two mice initially received an intraperitoneal (i.p.) injection 
of HiGom (12.5 µg/kg, diluted in PBS). Mice were closely monitored for two days to check for possible side effects. 
Every two days and for a total of three weeks thereafter the peptide dose was increased by 50%. The HiGom dose 
was safely incremented up to 15 mg/kg.
Ten female seven week old BALB/c FoxN1 nude mice were injected subcutaneously (s.c.) with 2.5 × 106 
MM96L cells in both flanks to develop two tumours per mouse. Two weeks later, when the tumours were of 
palpable size, we initiated treatment with HiGom (10 mg/kg). Briefly, mice were divided in two groups of five, 
which were treated with vehicle (PBS) or HiGom. Every two days and for a total of eight days, mice were injected 
i.p. with either HiGom or PBS in a final volume of 100 μl. To assess the impact of HiGom on tumour growth, 
the dimensions of the xenograft tumours were estimated using a digital calliper and applying the algorithm: 
Volume = a x b x b x 0.5, where “a” is the length and “b” is the measured breadth of the tumour lump (skin 
included)52. The effects of HiGom on tumour progression were estimated by calculating the fold-change in size 
versus the initial size prior to the first injection of HiGom (day 0). At the end of the experiment, mice were euth-
anised with CO2 and tumours were harvested for histology (Haemotoxylin and Eosin staining).
Zebrafish handling and care. Zebrafish embryos were obtained by mating adult zebrafish (Danio rerio, 
wild-type) that were maintained in 30 L of aquaria at a ratio of one fish per liter of water with a light-dark cycle of 
14:10 h and at a temperature of 28.5 °C according to previously described procedures53. All experimental proce-
dures, fish care and treatments were performed with the approval of the Animal Care and Use Committee of the 
University of Santiago de Compostela and the standard protocols of Spain (Directive 2012-63-DaUE). At the end 
of the experiments, zebrafish embryos were euthanised by tricaine overdose.
Zebrafish toxicity assays. A toxicity assay for AgGom and HiGom peptides was performed to assess the 
mortality of zebrafish embryos exposed to different peptide concentrations and at an incubation temperature of 
28.5 °C. This assay was performed using 12 replicates per concentration and is the result of three different inde-
pendent experiments. In brief, we exposed embryos at 72 h post fecundation (hpf) to the dissolved peptides for 
five days (until the embryos reached 192 hpf). The concentrations used were 0.01, 0.1, 1 and 10 µg/mL of AgGom 
or HiGom and the control was salt de-chlorinated tap water (SDTW). During the duration of the experiments, 
the mortality of the embryos was recorded at 24, 48 and 120 h post treatment.
Zebrafish embryo xenograft assays. Zebrafish embryos were collected and incubated at 28.5 °C dur-
ing the first 48 h hpf. At 48 hpf the embryos were anaesthetized with 0.003% tricaine (Sigma). MM96L human 
melanoma cells were cultured at 37 °C and 5% CO2 until they reached ~70% confluence. MM96L cells were 
then trypsinized and one million cells were harvested, labeled with Dil lipophilic dye and concentrated in 10 µL 
of phosphate-buffered saline (PBS) containing 2% polyvinyl-pyrrolidone 40 (PVP40) to avoid cell aggregation. 
Borosilicate glass capillary needles (1 mm O.D. × 0.75 mm I.D.; World Precision Instruments) were used to inject 
200–300 cells into the circulation of the embryos using a micromanipulator and a IM-31 Electric Microinjector 
(Narishige) with an output pressure of 34 kPa and 30 ms injection time. After the injection, embryos were incu-
bated for three days post-injection (hpi) at 34 °C in 30-mL Petri dishes containing SDTW.
Zebrafish embryo image analysis. Imaging of embryos was performed with an AZ-100 Nikon fluores-
cence stereomicroscope at 24 hpi and 96 hpi, which allowing live tracking of the labeled proliferating MM96L 
cells inside the zebrafish embryo. Analysis of the images taken at two different times (days 1 and 3) to monitor 
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progression of the injected cells, was performed using Quantifish Software54. This software quantifies the fluores-
cence of each image above a manually established threshold, yielding the integrated density of each image as an 
output. This measurement is the result of multiplying the number of positive pixels by the medium intensity of the 
fluorescence per each image. Integrated density was then processed to obtain a proliferation ratio and to compare 
the difference and normalized to the control conditions of the experiment.
Statistical analysis. Statistical analysis was performed using Graphpad Software (GraphPad Prism version 
7.00 for Windows, GraphPad Software, La Jolla California USA). All data represent a minimum of three inde-
pendent experiments and are expressed as the mean ± standard error of the mean (SEM). Statistical analyses 
were conducted using either a Student’s t-test or ANOVA for comparison between groups and control. Statistical 
significance was considered at *P < 0.05, **P < 0.01, ***P < 0.001 or ****P < 0.0001. When populations within 
groups were not normally distributed, a non-parametric Mann-Whitney test was used. For mouse in vivo studies, 
the permutation test was used to compare tumor progression between HiGom-treated and control groups. In 
zebrafish embryo xenograft assays, the outliers were identified using ‘Identify Outliers’ test followed by a t-test 
analysis. *P < 0.05 was considered statistically significant for all experiments.
Data availability. All data supporting this work are available within this article and the supplementary sec-
tion, or available from the authors upon request.
Data deposition. Metadata and annotated nucleotide sequences generated and utilised in this work were 
deposited on the European nucleotide archive (ENA) under project accession number ERA298588. HiGom pep-
tide can be found under accession HACE01000099.
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